VBI Vaccines Inc. and GlaxoSmithKline
(GSK) Biologicals recently made a partnership to determine how to best improve vaccine stability with VBI’s LPV Platform.
The platform, a proprietary formulation, is a process that allows researchers to develop biologics and vaccines that are more stable without losing potency. The platform uses a proprietary process and formulation to surround and protect the active component of the vaccine or biologic, the antigen.
Stability is an important part of vaccines, and whether a vaccine is stable affects its safety and potency. The stability also impacts how accessible the vaccine is for patients.
“With our partners, we seek to develop a next generation of vaccines and biologics with improved stability characteristics that allow for consistently safe and effective administration in both established and emerging markets,”
VBI President and CEO Jeff Baxter said. “We’re thrilled to be working with GlaxoSmithKline, a leading global health care company, to explore the potential of the LPV technology to their pipeline. This collaboration further validates the significant potential of our LPV Platform.”
According to the partnership, GSK has negotiated an exclusive license giving the company access to the LPV Platform within a specific field. Leaders at the two companies did not disclose any further details about the partnership or agreement.
